| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VERU Stock Overview
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.
Veru Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.25 |
| 52 Week High | US$23.99 |
| 52 Week Low | US$4.34 |
| Beta | -0.40 |
| 1 Month Change | 29.14% |
| 3 Month Change | 48.24% |
| 1 Year Change | 226.25% |
| 3 Year Change | 1,115.85% |
| 5 Year Change | 1,466.90% |
| Change since IPO | 235.85% |
Recent News & Updates
Veru Q3 2022 Earnings Preview
Veru (NASDAQ:VERU) is scheduled to announce Q3 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.15 (-400.0% Y/Y) and the consensus Revenue Estimate is $17.08M (-3.3% Y/Y). Over the last 1 year, VERU has beaten EPS estimates 25% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Oppenheimer said that a new analysis conducted by Veru (NASDAQ:VERU) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an Emergency Use Authorization from the U.S. FDA. The firm cited a new corporate presentation in making its call. The document indicates that the primary endpoint -- mortality rate by day 60 -- was met. In the treatment group, it was 20.2%, while in the placebo group, 45.1%. Sabizabulin also met second efficacy endpoints compared to placebo in terms of days in the ICU, on mechanical ventilation, and in the hospital. Read what Jefferies had to say in July about the prospects for sabizabulin.
Veru eligible for expedited review in U.K. for COVID-19 therapy
Clinical-stage biotech Veru (NASDAQ:VERU) announced on Monday that U.K. regulators agreed that the currently available safety and efficacy data for its experimental COVID-19 therapy sabizabulin would support an expedited review for a marketing application. The U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) has issued this view in relation to a potential marketing authorization application for the oral drug in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS). “With this decision, we plan to proceed toward the submission of our application as soon as possible,” Veru’s (VERU) Chief Executive Officer Mitchell Steiner noted. In June, the company announced it sought the FDA’s emergency use authorization for sabizabulin as a treatment for hospitalized COVID-19 patients who are at risk of ARDS.
Shareholder Returns
| VERU | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 93.5% | 2.0% | 3.6% |
| 1Y | 226.2% | -18.1% | -9.6% |
Return vs Industry: VERU exceeded the US Personal Products industry which returned -18.1% over the past year.
Return vs Market: VERU exceeded the US Market which returned -9.6% over the past year.
Price Volatility
| VERU volatility | |
|---|---|
| VERU Average Weekly Movement | 17.7% |
| Personal Products Industry Average Movement | 10.7% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VERU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: VERU's weekly volatility has decreased from 30% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 252 | Mitch Steiner | https://www.verupharma.com |
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer.
Veru Inc. Fundamentals Summary
| VERU fundamental statistics | |
|---|---|
| Market Cap | US$1.78b |
| Earnings (TTM) | -US$47.05m |
| Revenue (TTM) | US$52.41m |
34.0x
P/S Ratio-37.9x
P/E RatioIs VERU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERU income statement (TTM) | |
|---|---|
| Revenue | US$52.41m |
| Cost of Revenue | US$10.02m |
| Gross Profit | US$42.40m |
| Other Expenses | US$89.44m |
| Earnings | -US$47.05m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 80.89% |
| Net Profit Margin | -89.77% |
| Debt/Equity Ratio | 12.5% |
How did VERU perform over the long term?
See historical performance and comparison